Vyvanse vs. Ritalin: Abuse Risk Is Closer Than You Think
A review published August 8, 2026 in the Journal of Psychopharmacology put hard numbers behind a shift that’s been building for years: adult ADHD diagnosis is no longer a niche event. Among UK men aged 18-29, diagnoses rose roughly 20-fold and prescriptions rose roughly 50-fold between 2000 and 2018. Cambridge researchers Barbara J. Sahakian and Christelle Langley synthesized data from the UK, North America, Europe, and Asia — more than 154 million people across 13 countries — and the pattern held everywhere they looked. This isn’t a story about a handful of TikTok self-diagnoses. It’s a structural change in who gets identified, and it’s landing hardest on a group with the least infrastructure built for them: men in their 20s who are getting a diagnosis with no childhood 504 plan, no accommodations history, no “this is just how my brain works” narrative already in place.
That last part is the piece most coverage of this review is skipping past. A kid diagnosed at 8 grows up inside a system — an IEP or 504 plan, a school counselor, parents who’ve had a decade to adjust their expectations. An adult diagnosed at 24 gets a prescription and, if they’re lucky, a fifteen-minute follow-up appointment. Everything else — the routines, the workplace conversations, the years of unexplained failure they now have a name for — is theirs to build from nothing, usually while still working full-time and wondering why this wasn’t caught sooner.
TL;DR: What the Review Found
Question Answer The review Journal of Psychopharmacology, published Aug. 8, 2026 Who wrote it Barbara J. Sahakian and Christelle Langley, University of Cambridge The data UK records 2000-2018, England prescribing data 2021-25, and a 13-country dataset covering 154+ million people across North America, Europe, and Asia The headline stat UK men 18-29: roughly 20x more diagnoses, roughly 50x more prescriptions, 2000-2018 The ratio shift Male:female diagnosis ratio goes from about 4:1 in childhood to nearly 1:1 in adulthood England, 2021-22 Adult ADHD prescriptions jumped 32% — the first year more adults than children were prescribed since records began in 2015 What to do with it If you’re newly diagnosed as an adult, treat system-building as its own project — not an afterthought to the prescription
Sahakian and Langley weren’t running a new study — they were pulling together existing UK, European, North American, and Asian data to answer one question: is the “ADHD is exploding” feeling backed by numbers, or is it social-media noise? Their answer is unambiguous. Diagnoses and prescriptions rose across every age group they examined, in every region.
Children still show the largest raw increase in the UK data. But the group with the steepest relative climb is young adult men. A 20-fold jump in diagnoses and a 50-fold jump in prescriptions for men 18-29, over eighteen years, isn’t a rounding correction to an existing trend. It’s a population that was almost entirely missed the first time around, now getting caught on a second pass.
The 13-country dataset backs this up as a global pattern, not a UK quirk. Medication use climbed across North America, Europe, and Asia alike — different healthcare systems, different diagnostic cultures, same direction of travel.
In childhood, ADHD is diagnosed in boys at roughly 4 times the rate of girls. In adulthood, that ratio nearly closes to 1:1. The review frames this as evidence that the childhood ratio was never a true reflection of who has ADHD — it reflected who got noticed. Hyperactive boys got flagged by teachers. Inattentive, quieter presentations — more common in girls, and honestly plenty of boys too — got missed, and stayed missed until adulthood forced the issue.
That framing tracks with what we wrote about the diagnosis surge in women: both stories are the same correction, arriving from opposite ends. Women who masked well enough to avoid a childhood diagnosis are now getting identified in their 30s and 40s. Men who were dismissed as “lazy” or “just immature” instead of inattentive are now getting identified in their 20s. The 4:1-to-1:1 shift isn’t two separate trends. It’s one trend, viewed by sex.
The UK-specific numbers give this some texture. In England, adult ADHD prescriptions rose 32% in the 2021-22 year alone, compared to a 12% rise for children the following year. 2021-22 was also, per the review, the first year on record — records start in 2015 — that more adults than children were prescribed ADHD medication in England.
Flip that sentence around and it says something the raw percentages don’t: for the first time, the typical English ADHD patient isn’t a kid anymore. That’s a genuinely new thing for a condition that spent decades being coded almost entirely as pediatric. Waiting times for adult diagnosis in England, per the same review, still range from two to fifteen years depending on region — so the surge in diagnoses is happening despite a system that’s still badly bottlenecked, not because access suddenly got easy.
If you’re one of the people behind these numbers — diagnosed at 22, 26, 29, with a prescription in hand and nothing else — here’s the order that actually works, based on what tends to fall apart when people skip steps:
Here’s the actual gap this review points at, even though it’s not what the numbers are measuring directly. A kid who gets diagnosed young grows up with scaffolding installed early — extended time on tests, a case manager, parents who learn to break down instructions, years of trial and error absorbed by people other than the kid. An adult diagnosed at 25 has none of that. They have a diagnosis, maybe a prescription, and a job that doesn’t care that this is new information.
That’s a genuinely different starting position than “person who’s always known and adapted around it.” Research comparing late-diagnosed and childhood-diagnosed adults backs this up — the symptoms aren’t different, but the accumulated workaround experience is. A 24-year-old with a brand-new diagnosis is building executive-function infrastructure from zero, at an age when peers assume that infrastructure was settled in adolescence.
That means the newly diagnosed adult surge this review documents is really two problems stacked on top of each other: getting identified (which is finally happening, per these numbers), and then building a functioning system with none of the childhood runway everyone assumes you had. Most productivity advice — including a lot of what’s aimed at ADHD — assumes some baseline of self-knowledge that a two-month-old diagnosis just doesn’t include yet.
It’s not evidence of an “ADHD epidemic,” and the researchers don’t frame it that way. Rising diagnosis rates track most cleanly with better recognition — improved awareness among clinicians, telehealth lowering the barrier to an appointment, and diagnostic criteria that finally account for how ADHD shows up outside the hyperactive-white-boy stereotype the DSM was built around. A rate going up doesn’t tell you whether the underlying prevalence changed; it tells you detection changed. The review is transparent about that distinction, and so should anyone citing it.
It also doesn’t mean every new diagnosis is correct, or that overdiagnosis concerns raised elsewhere are baseless — just that, at a population level, the bigger documented problem for decades was adults with real ADHD going unidentified, not the reverse.
The 20-fold and 50-fold numbers make headlines, but the ratio shift is the more interesting finding here. A statistic converging from 4:1 to near 1:1 over one generation isn’t subtle — it’s a direct measurement of how badly the old diagnostic model missed people who didn’t look like the 1990s image of ADHD. Men in their 20s getting swept up in that correction now are, in a real sense, on the same side of this story as the women who got diagnosed in their 30s and 40s over the past several years: both groups got missed by a system built around a narrower picture of the condition than the condition actually is.
What we’d push back on is the implicit assumption in a lot of coverage that a diagnosis is the finish line. It’s the start of a much longer, mostly unglamorous project — figuring out what actually works for your specific brain, with no decade of childhood accommodations to build from. The review measures the diagnosis wave. Nobody’s measuring whether the healthcare system, or workplaces, or the productivity-app industry, are ready for what comes after it. Right now, mostly, they aren’t.
Sources: Sahakian, B.J. & Langley, C., “The increasing use of cognitive enhancing drugs by those with ADHD and neurotypical individuals,” Journal of Psychopharmacology, Aug. 8, 2026. Author explainer via The Conversation. Additional reporting from Medical Xpress.